Abstract | BACKGROUND/AIM: MATERIALS AND METHODS: Human osteosarcoma cell lines U2OS, SaOS2, MNNG/HOS (HOS) and 143B, were used. The MTAP gene was knocked out in U2OS with CRISPR/Cas9. 143B and HOS have an MTAP deletion and SaOS2 is positive for MTAP. MTAP was determined by western blotting. The four cell lines were compared for sensitivity to recombinant methioninase (rMETase). RESULTS: MTAP-deleted osteosarcoma cell lines MNNG/HOS and 143B were significantly more sensitive to rMETase than MTAP-positive osteosarcoma cell lines U2OS and SaOS2. In addition, MTAP knock-out U2OS cells were more sensitive to rMETase than the parental MTAP-positive U2OS cells. CONCLUSION: The present results demonstrated that the absence of MTAP sensitizes osteosarcoma cells to methionine restriction by rMETase, a promising clinical strategy.
|
Authors | Yusuke Aoki, Yasunori Tome, Qinghong Han, Jun Yamamoto, Kazuyuki Hamada, Noriyuki Masaki, Yutaro Kubota, Michael Bouvet, Kotaro Nishida, Robert M Hoffman |
Journal | Cancer genomics & proteomics
(Cancer Genomics Proteomics)
2022 May-Jun
Vol. 19
Issue 3
Pg. 299-304
ISSN: 1790-6245 [Electronic] Greece |
PMID | 35430564
(Publication Type: Journal Article)
|
Copyright | Copyright© 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. |
Chemical References |
- Recombinant Proteins
- Methylnitronitrosoguanidine
- Methionine
- Purine-Nucleoside Phosphorylase
- 5'-methylthioadenosine phosphorylase
- Carbon-Sulfur Lyases
- L-methionine gamma-lyase
|
Topics |
- Bone Neoplasms
(genetics, metabolism, therapy)
- Carbon-Sulfur Lyases
(genetics, metabolism)
- Cell Line, Tumor
- Humans
- Methionine
(deficiency, metabolism, pharmacology)
- Methylnitronitrosoguanidine
- Osteosarcoma
(genetics, metabolism, therapy)
- Purine-Nucleoside Phosphorylase
(deficiency, genetics, metabolism)
- Recombinant Proteins
(pharmacology)
|